Qiuxiang Ou, PhD
About Qiuxiang Ou, PhD
Qiuxiang Ou - Director, Oncology Translational Research
Qiuxiang Ou serves as the Director of Oncology Translational Research. In this role, their responsibilities include overseeing key research projects and guiding research initiatives aimed at improving cancer treatment outcomes. Their work primarily focuses on the translation of laboratory findings into clinical applications, particularly in the field of oncology.
Qiuxiang Ou and Princess Margaret Cancer Centre Collaboration
Qiuxiang Ou co-published a significant study with Princess Margaret Cancer Centre. This study investigated the use of circulating tumor DNA (ctDNA) as a prognostic biomarker for immunotherapy. This collaboration marks an important step in advancing the understanding of how ctDNA can be utilized to predict patient outcomes in immunotherapy treatments.
Qiuxiang Ou and ctDNA Research in Immunotherapy Trials
In their research, Qiuxiang Ou has explored the potential of ctDNA levels as predictors of treatment benefit in phase I/II immunotherapy trials. This work aims to enhance the ability to forecast treatment outcomes, thereby contributing to the optimization of therapeutic strategies for cancer patients.
Qiuxiang Ou - Publications in JCO Precision Oncology
Qiuxiang Ou has authored research that has been published in the JCO Precision Oncology journal. This publication includes findings related to the use of ctDNA in predicting treatment responses and benefits in cancer immunotherapy, providing valuable insights into precision medicine.